Literature DB >> 3812427

A case-control study of breast cancer stratified by estrogen receptor status.

J L Stanford, M Szklo, C C Boring, L A Brinton, E A Diamond, R S Greenberg, R N Hoover.   

Abstract

A population-based case-control study was conducted to examine whether tumor estrogen receptor status differentiated risk factor patterns for breast cancer. From December 1980 to December 1982, 458 women with newly diagnosed breast cancer and 568 control women, aged 20-54 years, from the Atlanta, Georgia, metropolitan area were interviewed. On the basis of tumor estrogen receptor results, cases were classified as receptor-positive or receptor-negative. Intercase analysis showed that age was positively and significantly associated with estrogen receptor-positive breast cancer (p = 0.001); the relative risk for an estrogen receptor-positive as opposed to an estrogen receptor-negative tumor was elevated threefold among women aged 50-54 years compared with those aged less than 35 years. In the case-control analysis, race was the only individual factor that demonstrated a significant difference in the risk for estrogen receptor-positive versus estrogen receptor-negative cancer (p less than 0.05), with blacks being at a 25% excess risk for estrogen receptor-negative cancer compared with whites. Although a history of benign breast disease was a risk factor for both positive and negative tumors, the association was stronger for the estrogen receptor-positive tumors. Postmenopausal women were at a lower risk for both cancer subtypes compared with premenopausal women. Compared with non-users, women who had ever taken oral contraceptives had a 16% decrease in the risk for receptor-positive cancer and a 22% increase in the risk for receptor-negative cancer. These results are consistent with the notion that certain exposure variables may relate to hormonal status, possibly by augmentation or suppression of estrogen receptor activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3812427     DOI: 10.1093/oxfordjournals.aje.a114519

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  21 in total

1.  Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.

Authors:  Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Breast cancer incidence in young women by estrogen receptor status and race.

Authors:  J L Stanford; R S Greenberg
Journal:  Am J Public Health       Date:  1989-01       Impact factor: 9.308

3.  Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study.

Authors:  Swann Arp Adams; Charles E Matthews; James R Hebert; Charity G Moore; Joan E Cunningham; Xiou-Oi Shu; Jeanette Fulton; Yutang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

4.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

5.  Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Authors:  James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

6.  Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions.

Authors:  Nancy Krieger; Jarvis T Chen; James H Ware; Afamia Kaddour
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

7.  A hospital-based case-control study of breast-cancer risk factors by estrogen and progesterone receptor status.

Authors:  K Y Yoo; K Tajima; S Miura; M Yoshida; H Murai; T Kuroishi; Y Lee; H Risch; R Dubrow
Journal:  Cancer Causes Control       Date:  1993-01       Impact factor: 2.506

8.  Polychlorinated biphenyls and breast cancer risk by combined estrogen and progesterone receptor status.

Authors:  Jennifer A Rusiecki; Theodore R Holford; Shelia H Zahm; Tonzhang Zheng
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  Breast cancer screening, with particular reference to the concept of 'high risk' groups.

Authors:  F De Waard; H J Collette; J J Rombach; C Collette
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

10.  Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Authors:  Agnès Fournier; Alban Fabre; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Franco Berrino; Françoise Clavel-Chapelon
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.